Paul Tudor Jones's CPRX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 20,395 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $504,980, representing 0.00% of the portfolio. First purchased in 2022-Q3, this short-term holding has been held for 7 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in CPRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2024, adding 59,552 shares. Largest reduction occurred in Q3 2025, reducing 76,088 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +20,395 | New Buy | 20,395 | $24.76 |
| Q3 2025 | -76,088 | Sold Out | 0 | $0.00 |
| Q2 2025 | +14,502 | Add 23.55% | 76,088 | $21.70 |
| Q1 2025 | +2,034 | Add 3.42% | 61,586 | $24.25 |
| Q4 2024 | +59,552 | New Buy | 59,552 | $20.87 |
| Q4 2022 | -73,965 | Sold Out | 0 | $0.00 |
| Q3 2022 | +73,965 | New Buy | 73,965 | $12.83 |
Paul Tudor Jones's Catalyst Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q3 2022, acquiring 73,965 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Catalyst Pharmaceuticals, Inc. (CPRX) for 7 quarters since Q3 2022.
Paul Tudor Jones's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q3 2022, adding 73,965 shares worth $949,000.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 20,395 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $504,980.
As of the Q1 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 76,088 shares, as reported at the end of Q2 2025.